Popular Trials
mTOR inhibitor
Topical Rapamycin for Vitiligo
This trial tests if a daily cream with rapamycin can help treat vitiligo, a skin condition causing color loss. Participants will use the cream on one side of their body and a different cream on the other for several months. The study will also check patient satisfaction and any side effects. Rapamycin has been studied for its potential to stabilize cyst growth in ADPKD, but larger trials showed no benefit on kidney function.
Monoclonal Antibodies
MK-6194 for Vitiligo
This trial is testing a new medication called MK-6194 to see if it can help people with non-segmental vitiligo. The goal is to determine if MK-6194 can reduce the white patches on their skin by helping repigment these areas. Researchers will compare the results over several months.
Janus Kinase (JAK) Inhibitor
Ritlecitinib for Vitiligo
This trial is testing a medication called ritlecitinib, which is taken as oral capsules. It aims to help adults and adolescents who have non-segmental vitiligo, a condition that causes skin to lose its color. The medication works by managing the immune system to stop the skin from losing its color.
Melanocortin receptor agonist
Afamelanotide for Vitiligo
This trial is testing a drug called afamelanotide to see if it can help people with vitiligo, a condition that causes skin to lose its color. The drug aims to restore skin color by increasing melanin production.
Popular Filters
Phase 3 Trials
Janus Kinase (JAK) Inhibitor
Upadacitinib for Vitiligo
This trial will evaluate if the drug upadacitinib is safe and effective in treating vitiligo, a chronic autoimmune skin disease. 540 participants will be enrolled worldwide to receive either upadacitinib or a placebo in Period A, followed by upadacitinib in Period B.
Melanocortin Receptor Agonist
SCENESSE + NB-UVB Light for Vitiligo
This trial is testing a new treatment for vitiligo that combines a drug called afamelanotide with a special type of light therapy. The goal is to see if this combination works better than the light therapy alone in helping people with vitiligo regain their skin color.
Janus Kinase (JAK) Inhibitor
Povorcitinib for Vitiligo
This trial is testing a medication called povorcitinib to see if it can help people with nonsegmental vitiligo, a condition where skin loses its color in patches. The medication might work by stopping the immune system from attacking the cells that give skin its color. Researchers want to find out if it is effective and safe for these patients.
Tyrosine Kinase Inhibitor
Povorcitinib for Vitiligo
This trial is testing a medication called povorcitinib to see if it can help people with nonsegmental vitiligo, a condition that causes white patches on the skin. The medication might work by calming the immune system to prevent it from attacking the skin. Researchers want to find out if this treatment is both effective and safe.
Janus Kinase (JAK) Inhibitor
Ritlecitinib for Vitiligo
This trial is testing ritlecitinib, a medicine for treating vitiligo, in adults with nonsegmental vitiligo. The medicine works by protecting skin color cells from being destroyed by the immune system. The study will compare ritlecitinib to see if it is safe and effective. Ritlecitinib is being tested for its efficacy in treating alopecia areata and vitiligo.
Trials With No Placebo
Melanocortin Receptor Agonist
SCENESSE + NB-UVB Light for Vitiligo
This trial is testing a new treatment for vitiligo that combines a drug called afamelanotide with a special type of light therapy. The goal is to see if this combination works better than the light therapy alone in helping people with vitiligo regain their skin color.
Procedure
Spray-On Skin Cells for Vitiligo
This trial tests a new treatment for people with stable vitiligo, a condition where patches of skin lose their color. The treatment uses the RECELL Device to create a mixture of the patient's own skin cells, which is then applied to the discolored areas. Patients also use a special light therapy at home to help improve the results.
Janus Kinase (JAK) Inhibitor
Ruxolitinib Cream for Vitiligo
This trial involves people with a type of vitiligo affecting their genital area using a special cream called ruxolitinib. The cream helps reduce skin inflammation to restore color to white patches. Ruxolitinib is known for its ability to help with repigmentation and is considered safe to use.
Frequently Asked Questions
Introduction to vitiligo
What are the top hospitals conducting vitiligo research?
When it comes to cutting-edge clinical trials for the treatment of vitiligo, several hospitals around the world are at the forefront of research and innovation. In Vancouver, Canada, The Skin care Center at Vancouver General Hospital is making significant strides with four ongoing vitiligo trials and a total of four trials conducted since its first recorded trial in 2013. Meanwhile, on the sunny coast of Irvine, California, researchers at the University of California are actively engaged in two vitiligo trials and have completed six previous studies since their initial exploration into this condition began in 2017.
Further south lies Charleston's Medical University of South carolina, where dedicated experts have initiated two active vitiligo trials. Their commitment to finding effective treatments is evident as they continue building upon their knowledge gained from four prior investigations dating back to 2020. Heading north again to Calgary, Canada we encounter Dermatology Research Institute which has also embraced vitiligo research with enthusiasm by currently conducting two clinical tests while having successfully organized five earlier experiments that started off just recently during 2019.
Lastly but not leastly located in Worcester Massachusetts one can find another powerhouse within this field;the University Of Massachusetts Medical School.They have made notable advances through participating as an integral part conducting multiple types involving this skin condition including two presently ongoing.In addition,five additional set-ups had been launched under their supervision right after commencing initial survey held way back throughout year 2018.
These esteemed medical institutions exemplify a global dedication towards understanding and treating vitiligo—a complex condition characterized by depigmented patches on the skin—while offering hope for those affected by it. Through collaborative efforts across these hospitals and other leading centers worldwide pursuing similar investigations into innovative therapies,the future appears bright for individuals living with this enigmatic disorder
Which are the best cities for vitiligo clinical trials?
When considering vitiligo clinical trials, several cities emerge as prominent hubs for research and development. Worcester in Massachusetts showcases 5 ongoing trials investigating treatments like Study Treatment, Oral Metformin, and Ritlecitinib 50 mg. In Detroit, Michigan, researchers are actively studying NB-UVB phototherapy, Study Treatment, AMG 714 among other interventions through their 5 active trials. Meanwhile, Boston in Massachusetts also takes part with its 4 ongoing trials exploring Ritlecitinib 50 mg, NB-UVB phototherapy, AMG 714 alongside other potential therapies. Vancouver in British Columbia contributes to the field with its own set of 4 active trials examining Topical PUVA treatment options and Low intensity red laser therapies among others. Finally, Irvine in California engages in vitiligo clinical research with three active trials focusing on interventions such as AMG714 and Study Treatments. These cities collectively present opportunities for individuals affected by vitiligo to access innovative clinical trials that aim to advance understanding and improve outcomes for this condition.
Which are the top treatments for vitiligo being explored in clinical trials?
Vitiligo research is making strides in clinical trials, with two standout treatments at the forefront. The first is rapamycin, currently being explored in one active trial specifically for vitiligo. This innovative treatment was listed for the first time in 2022 and shows promising potential. Another notable approach is NB-UVB phototherapy, which has caught researchers' attention with its positive outcomes. It is currently involved in one active trial and three all-time vitiligo trials since its introduction in 2017. These cutting-edge treatments offer hope for those affected by vitiligo, paving the way towards improved management of this challenging condition.
What are the most recent clinical trials for vitiligo?
Groundbreaking progress is being made in the realm of vitiligo treatment, with recent clinical trials showcasing promising developments. One such trial focuses on the use of oral metformin, a medication traditionally prescribed for diabetes management but now showing potential in reducing depigmentation caused by vitiligo. Another compelling study examines ruxolitinib cream—a topical formulation that holds promise for repigmenting affected skin areas. Additionally, ritlecitinib 50 mg has entered Phase 3 trials and aims to provide an effective therapeutic option for those living with vitiligo. Joining these advancements are afamelanotide and NBUVB phototherapy studies which explore alternative approaches towards treating this challenging condition. These innovative trials bring hope to individuals living with vitiligo as they pave the way for improved treatments and quality of life outcomes.
What vitiligo clinical trials were recently completed?
Recent clinical trials have made significant strides in advancing the treatment of vitiligo. In November 2021, the Medical University of South carolina completed a trial investigating the potential of Excimer laser therapy. Prior to that, in June 2021, Incyte Corporation wrapped up two groundbreaking trials: one exploring Ruxolitinib cream and another focused on Upadacitinib. Additionally, Incyte Corporation conducted a trial for INCB054707 which concluded in May 2021. Lastly, Sun Pharma Global FZE successfully completed their AS012 trial in January 2021. These important studies underscore the ongoing efforts to develop effective therapies for vitiligo patients across various research institutions and pharmaceutical companies.